IMAX CORP·4

Mar 12, 4:35 PM ET

GELFOND RICHARD L 4

4 · IMAX CORP · Filed Mar 12, 2026

Research Summary

AI-generated summary of this filing

Updated

IMAX CEO Richard Gelfond Exercises Options, Sells 121,220 Shares

What Happened
Richard L. Gelfond, CEO of IMAX Corp (IMAX), exercised stock options to acquire 121,220 common shares at $31.40 per share (total exercise cost $3,806,308) on March 10, 2026, and sold those 121,220 shares in the open market the same day at $40.10 per share for gross proceeds of $4,860,837. The transactions produced gross proceeds roughly $1,054,529 above the exercise cost (before taxes and fees). The Form 4 shows both the option-to-share conversion and the subsequent sale.

Key Details

  • Transaction date: 2026-03-10. Form filed: 2026-03-12 (timely filing).
  • Exercise (conversion of derivative): 121,220 shares acquired at $31.40 each — total cost $3,806,308.
  • Open-market sale: 121,220 shares sold at $40.10 each — gross proceeds $4,860,837.
  • Post-transaction holdings (per footnote): options outstanding 1,697,475; restricted share units 231,562; common shares 765,002.
  • Footnotes: F1 states conversion occurred pursuant to a 10b5-1 plan (footnote lists plan date as December 9, 2026); F2–F3 note these were options issued in 2016 with vesting installments and an expiration date of June 7, 2026; F4 gives remaining balances after the transactions.
  • Transaction codes: conversion is shown as derivative conversion (C); sale is an open-market disposition (S).

Context

  • This was an exercise of previously granted options followed by an immediate sale of the resulting shares — effectively a cashless exercise/sale of newly acquired shares.
  • Such transactions are often routine for executives exercising and selling vested options; they are factual disclosures of trading activity and not a direct statement of future company prospects.

Insider Transaction Report

Form 4
Period: 2026-03-10
GELFOND RICHARD L
DirectorChief Executive Officer
Transactions
  • Conversion

    common shares

    [F1]
    2026-03-10$31.40/sh+121,220$3,806,308886,222 total
  • Sale

    common shares

    2026-03-10$40.10/sh121,220$4,860,837765,002 total
  • Conversion

    stock options (to buy)

    [F2][F3][F4]
    2026-03-10$31.40/sh121,220$3,806,308365,064 total
    Exercise: $31.40From: 2026-03-10Exp: 2026-06-07common shares (121,220 underlying)
Holdings
  • common shares (opening balance)

    765,002
Footnotes (4)
  • [F1]Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2026.
  • [F2]These options were issued in 2016 and are set to expire on June 7, 2026.
  • [F3]The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016.
  • [F4]This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,697,475, 231,562 and 765,002, respectively.
Signature
/s/ Richard L. Gelfond|2026-03-12

Documents

1 file
  • 4
    marketforms-72488.xmlPrimary

    PRIMARY DOCUMENT